GSK turns to R&D jobs for savings
Executive Summary
GlaxoSmithKline announced plans to cut R&D employment in the U.K. and U.S. by 850 positions, or about 6 percent of its global R&D staff of 15,000, as part of an ongoing restructuring program. In July, the company announced it is creating small drug performance units, which will operate within its Centers of Excellence for Drug Discovery. The centers focus on particular therapeutic areas; the new units, consisting of five to 80 scientists, concentrate on specific biological pathways and will compete for funding (1"The Pink Sheet," July 28, 2008, p. 10)
You may also be interested in...
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.